- Home
- NSPR
NSPR
InspireMD Inc.
as of 03-19-2026 3:59pm EST
$1.67
$0.12
-6.70%
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | MIAMI |
| Market Cap: | 77.5M | IPO Year: | 2009 |
| Target Price: | $4.00 | AVG Volume (30 days): | 35.1K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.76 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.51 - $2.93 | Next Earning Date: | 03-18-2026 |
| Revenue: | $2,310,000 | Revenue Growth: | -18.03% |
| Revenue Growth (this year): | 22.91% | Revenue Growth (next year): | 72.30% |
| P/E Ratio: | -2.35 | Index: | N/A |
| Free Cash Flow: | -36765000.0 | FCF Growth: | N/A |
AI-Powered NSPR Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 66.46%
66.46%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of InspireMD Inc. (NSPR)
Gleason Shane Thomas
Sell
Chief Commercial Officer
NSPR Feb 2, 2026
Avg Cost/Share
$1.60
Shares
2,000
Total Value
$3,208.00
Owned After
1,139,177
SEC Form 4
Gleason Shane Thomas
Sell
Chief Commercial Officer
NSPR Jan 30, 2026
Avg Cost/Share
$1.63
Shares
2,900
Total Value
$4,729.90
Owned After
1,139,177
SEC Form 4
Gleason Shane Thomas
Sell
Chief Commercial Officer
NSPR Jan 29, 2026
Avg Cost/Share
$1.65
Shares
5,000
Total Value
$8,250.00
Owned After
1,139,177
SEC Form 4
Gleason Shane Thomas
Sell
Chief Commercial Officer
NSPR Jan 28, 2026
Avg Cost/Share
$1.65
Shares
12,395
Total Value
$20,464.15
Owned After
1,139,177
SEC Form 4
Gleason Shane Thomas
Sell
Chief Commercial Officer
NSPR Jan 27, 2026
Avg Cost/Share
$1.66
Shares
4,781
Total Value
$7,955.58
Owned After
1,139,177
SEC Form 4
Gleason Shane Thomas
Sell
Chief Commercial Officer
NSPR Jan 22, 2026
Avg Cost/Share
$1.57
Shares
8,411
Total Value
$13,238.91
Owned After
1,139,177
SEC Form 4
Gleason Shane Thomas
Sell
Chief Commercial Officer
NSPR Jan 21, 2026
Avg Cost/Share
$1.62
Shares
17,593
Total Value
$28,553.44
Owned After
1,139,177
SEC Form 4
Gleason Shane Thomas
Sell
Chief Commercial Officer
NSPR Jan 20, 2026
Avg Cost/Share
$1.59
Shares
2,955
Total Value
$4,710.27
Owned After
1,139,177
SEC Form 4
Gleason Shane Thomas
Sell
Chief Commercial Officer
NSPR Jan 16, 2026
Avg Cost/Share
$1.61
Shares
2,250
Total Value
$3,627.00
Owned After
1,139,177
SEC Form 4
Gleason Shane Thomas
Sell
Chief Commercial Officer
NSPR Jan 15, 2026
Avg Cost/Share
$1.58
Shares
2,909
Total Value
$4,593.31
Owned After
1,139,177
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Gleason Shane Thomas | NSPR | Chief Commercial Officer | Feb 2, 2026 | Sell | $1.60 | 2,000 | $3,208.00 | 1,139,177 | |
| Gleason Shane Thomas | NSPR | Chief Commercial Officer | Jan 30, 2026 | Sell | $1.63 | 2,900 | $4,729.90 | 1,139,177 | |
| Gleason Shane Thomas | NSPR | Chief Commercial Officer | Jan 29, 2026 | Sell | $1.65 | 5,000 | $8,250.00 | 1,139,177 | |
| Gleason Shane Thomas | NSPR | Chief Commercial Officer | Jan 28, 2026 | Sell | $1.65 | 12,395 | $20,464.15 | 1,139,177 | |
| Gleason Shane Thomas | NSPR | Chief Commercial Officer | Jan 27, 2026 | Sell | $1.66 | 4,781 | $7,955.58 | 1,139,177 | |
| Gleason Shane Thomas | NSPR | Chief Commercial Officer | Jan 22, 2026 | Sell | $1.57 | 8,411 | $13,238.91 | 1,139,177 | |
| Gleason Shane Thomas | NSPR | Chief Commercial Officer | Jan 21, 2026 | Sell | $1.62 | 17,593 | $28,553.44 | 1,139,177 | |
| Gleason Shane Thomas | NSPR | Chief Commercial Officer | Jan 20, 2026 | Sell | $1.59 | 2,955 | $4,710.27 | 1,139,177 | |
| Gleason Shane Thomas | NSPR | Chief Commercial Officer | Jan 16, 2026 | Sell | $1.61 | 2,250 | $3,627.00 | 1,139,177 | |
| Gleason Shane Thomas | NSPR | Chief Commercial Officer | Jan 15, 2026 | Sell | $1.58 | 2,909 | $4,593.31 | 1,139,177 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q3 Q3 2025 Earnings
8-K SELL Nov 4, 2025 · 100% conf.
2025
Q3
Q3 2025 Earnings
8-K SELLNov 4, 2025 · 100% conf.
AI Prediction SELL
1D
-2.48%
$2.07
Act: -0.71%
5D
-4.55%
$2.03
Act: -23.29%
20D
-8.44%
$1.95
Act: -10.12%
Price: $2.13 Prob +5D: 0% AUC: 1.000
0001493152-25-020718
false 0001433607
0001433607
2025-11-04 2025-11-04
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): November 4, 2025
InspireMD, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
001-35731
26-2123838
(Commission
File Number)
(IRS Employer
Identification No.)
6303 Waterford District Drive, Suite 215
Miami, Florida
33126
(Address of Principal Executive Offices)
(Zip Code)
(888) 776-6804
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
NSPR
The Nasdaq Capital Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On November 4, 2025, InspireMD, Inc. (the “Company”) issued a press release announcing its financial and operating results and recent highlights for the three and nine months ended September 30, 2025. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K that is furnished pursuant to this Item 2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 7.01 Regulation FD Disclosure.
On November 4, 2025, the Company made available an updated investor presentation. A copy of the presentation is attached hereto as Exhibit 99.2 and incorporated by reference in this Item 7.01. A copy of the presentation is also available on the Company’s website https://www.inspiremd.com/en/investors/.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K that is furnished pursuant to this Item 7.01 shall not be deemed to be “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number
Description
99.1
Press release, dated November 4, 2025 (furnished herewith pursuant to Item 2.02)
99.2
Investor Presentation November 2025 (furnished herewith pursuant to Item 7.01)
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INSPIREMD, INC.
Date: November 4, 2025 By: /s/ Michael Lawless
Name: Michael Lawless
Title: Chief Financial Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 5, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 5, 2025
0001641172-25-022159
false 0001433607
0001433607
2025-08-05 2025-08-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): August 5, 2025
InspireMD, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
001-35731
26-2123838
(Commission
File Number)
(IRS
Employer
Identification No.)
6303 Waterford District Drive, Suite 215
Miami, Florida
33126
(Address of Principal Executive Offices)
(Zip Code)
(888) 776-6804
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
NSPR
The Nasdaq Capital Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On August 5, 2025, InspireMD, Inc. (the “Company”) issued a press release announcing its financial and operating results and recent highlights for the three and six months ended June 30, 2025. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K that is furnished pursuant to this Item 2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 7.01 Regulation FD Disclosure.
On August 5, 2025, the Company made available an updated investor presentation. A copy of the presentation is attached hereto as Exhibit 99.2 and incorporated by reference in this Item 7.01. A copy of the presentation is also available on the Company’s website https://www.inspiremd.com/en/investors/.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K that is furnished pursuant to this Item 7.01 shall not be deemed to be “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number
Description
99.1
Press release, dated August 5, 2025 (furnished herewith pursuant to Item 2.02)
99.2
Investor Presentation August 2025 (furnished herewith pursuant to Item 7.01)
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INSPIREMD, INC.
Date: August 5, 2025 By: /s/ Michael Lawless
Name: Michael Lawless
Title: Chief Financial Officer
2025 Q1 Q1 2025 Earnings
8-K May 9, 2025
2025
Q1
Q1 2025 Earnings
8-KMay 9, 2025
0001641172-25-009364
false 0001433607
0001433607
2025-05-09 2025-05-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 9, 2025
InspireMD, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
001-35731
26-2123838
(Commission
File Number)
(IRS
Employer
Identification No.)
4 Menorat Hamaor St. Tel Aviv, Israel
6744832
(Address of Principal Executive Offices)
(Zip Code)
(888) 776-6804
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
NSPR
The Nasdaq Capital Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On May 9, 2025, InspireMD, Inc. issued a press release announcing its financial and operating results and recent highlights for the first quarter ended March 31, 2025. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K that is furnished pursuant to this Item 2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number
Description
99.1
Press release, dated May 9, 2025 (furnished herewith pursuant to Item 2.02)
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INSPIREMD, INC.
Date: May 9, 2025 By: /s/ Craig Shore
Name: Craig Shore
Title: Chief Financial Officer
Latest InspireMD Inc. News
NSPR Breaking Stock News: Dive into NSPR Ticker-Specific Updates for Smart Investing
GlobeNewswire
InspireMD Reports Fourth Quarter and Full Year 2025 Financial Results
📊
AI Sentiment
Positive
7/10
Compare NSPR vs Leading Stocks
See how NSPR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NSPR InspireMD Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.